<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961373</url>
  </required_header>
  <id_info>
    <org_study_id>Neo-D2plus trial</org_study_id>
    <nct_id>NCT03961373</nct_id>
  </id_info>
  <brief_title>Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer</brief_title>
  <acronym>Neo-D2plus</acronym>
  <official_title>Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Siena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the patients with histological evidence of adenocarcinoma of the stomach will&#xD;
      be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions&#xD;
      of NAC and obtaining informed consent, they will be registered and randomized to receive&#xD;
      surgical D2 vs. D2plus lymphadenectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multi-centre phase III, two-group, randomized and controlled trial&#xD;
      designed to prove superiority of the experimental treatment arm (neo-adjuvant chemotherapy&#xD;
      and super-extended lymphadenectomy).&#xD;
&#xD;
      The trial population consists of patients who have histologically confirmed adenocarcinoma of&#xD;
      the stomach with locally advanced primary tumour and no evidence of distant metastases (stage&#xD;
      IIA-IIIC gastric cancer). The lymph node clinical metastases, before neo-adjuvant&#xD;
      chemotherapy, must be limited to the first and second compartments (stations 1-12).&#xD;
&#xD;
      STANDARD GROUP: Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy.&#xD;
&#xD;
      Patients who are assigned to neoadjuvant chemotherapy+ surgical D2 treatment group will&#xD;
      undergo either subtotal or total gastrectomy, depending on the location of the primary&#xD;
      tumour. Standardized D2-lymph node dissection is required with specific information about&#xD;
      lymph node stations.&#xD;
&#xD;
      EXPERIMENTAL GROUP: Neoadjuvant chemotherapy + surgical gastrectomy with D2plus&#xD;
      lymphadenectomy.&#xD;
&#xD;
      Patients who are assigned to neoadjuvant chemotherapy + surgical D2plus extended&#xD;
      lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending&#xD;
      on the location of the primary tumour. Standardized D2 lymph node dissection plus resection&#xD;
      of stations 8p, 12b/p, 13, 14v, 16a2/b1 is required with specific information about lymph&#xD;
      node stations.&#xD;
&#xD;
      In both groups, surgical treatment should be performed within 4-6 weeks after the end of the&#xD;
      last cycle of NAC.&#xD;
&#xD;
      The primary objective of this study is to compare overall and cancer-related survival between&#xD;
      D2 and D2+ lymphadenectomy following neo-adjuvant chemotherapy for resectable gastric cancer.&#xD;
&#xD;
      In addition, response to chemotherapy, resection rate, quality of life, complications&#xD;
      attributable to surgical intervention / side effects of chemotherapy and the duration of&#xD;
      hospitalization will be evaluated.&#xD;
&#xD;
      Sample size estimation was performed, to detect the minimum number of patients to be&#xD;
      recruited in each arm. A two-sided log rank test with an overall sample size of 539 subjects,&#xD;
      of which 270 are in group 1 and 269 are in group 2.&#xD;
&#xD;
      Data will be analyzed using SPSS software. Level of significance will be defined as 5%.&#xD;
&#xD;
      The trial will be open for recruitment from October 2018 to September 2023.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>This outcome measure will be estimated from the time of randomization to the date of death or last follow up visit, assessed approximately 5 years after the disease diagnosis.</time_frame>
    <description>Overall survival analysis will be analysed during follow up visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free-survival</measure>
    <time_frame>This outcome measure will be estimated from the time of randomization to the date of recurrence, assessed approximately 5 years after the disease diagnosis.</time_frame>
    <description>That part will also be analysed during follow up visits. The recurrence has to be documented in radiological, endoscopic or pathological examination, when possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>This outcome measure will be assessed approximately 3 month after the operation date.</time_frame>
    <description>Severity of post-operative complications will be analysed using Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative mortality</measure>
    <time_frame>Within 30 days from operation or during the hospital stay</time_frame>
    <description>Deaths after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection</measure>
    <time_frame>This outcome measure will be assessed approximately 3 month after the operation date.</time_frame>
    <description>Absence of microscopic (R1) or macroscopic (R2) residual tumor after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of completion of protocol treatment</measure>
    <time_frame>This outcome measure will be assessed approximately 12 month after the date of enrollment.</time_frame>
    <description>Percentage of patients who will complete the protocol treatment, including adjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">539</enrollment>
  <condition>Locally Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy with D2 lymphadenectomy</intervention_name>
    <description>Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.</description>
    <arm_group_label>Standard Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy with D2plus lymphadenectomy</intervention_name>
    <description>Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal or greater than 18 years&#xD;
&#xD;
          -  IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment&#xD;
             with NAC. Not including gastro-oesophageal junction/cardia carcinoma but only Siewert&#xD;
             3, without any previous treatment (surgery and / or chemotherapy) for this diagnosis&#xD;
&#xD;
          -  Lack in CT scan of following:&#xD;
&#xD;
               1. Mediastinal lymph nodes&#xD;
&#xD;
               2. Lung metastases&#xD;
&#xD;
               3. Peritoneal metastases&#xD;
&#xD;
               4. Liver metastases&#xD;
&#xD;
               5. Pleural effusion, ascites&#xD;
&#xD;
               6. Metastases to para-aortic lymph nodes No 16a2/b1&#xD;
&#xD;
               7. Metastases to lymph nodes located in the &quot;posterior&quot; area (8p, 12 b/p, 13)&#xD;
&#xD;
               8. Extra-regional lymph node metastases&#xD;
&#xD;
          -  ECOG performance status â‰¤ 2&#xD;
&#xD;
          -  No prior radio- or chemotherapy conflicting with the treatment of gastric cancer&#xD;
&#xD;
          -  No oesophageal invasion, or invasion &lt;=3cm&#xD;
&#xD;
          -  Negative peritoneal washing cytology findings and no peritoneal metastases in staging&#xD;
             laparoscopy&#xD;
&#xD;
          -  No gastric stump cancer&#xD;
&#xD;
          -  No signs of cervical and subclavear lymph nodes or distal metastases&#xD;
&#xD;
          -  Patient's consent form obtained, signed and dated before beginning specific protocol&#xD;
             procedures&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for any sort of appropriate chemotherapy according to local&#xD;
             standards&#xD;
&#xD;
          -  Linitis plastica&#xD;
&#xD;
          -  Second uncontrolled malignant tumour (synchronous or metachronous (last 5 years) other&#xD;
             than Cis or mucosal cancer&#xD;
&#xD;
          -  Neoplasms involving the esophago-gastric junction (Siewert types I and II)&#xD;
&#xD;
          -  Expected unresectability after neo-adjuvant treatment or progression in metastases&#xD;
&#xD;
          -  Emergency surgery due to bleeding or perforation&#xD;
&#xD;
          -  Uncontrolled infections&#xD;
&#xD;
          -  Other serious underlying medical conditions that could impair the ability of the&#xD;
             patient to participate in the study&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Significant neurologic or psychiatric disorders&#xD;
&#xD;
          -  Severe cardiac illness (NYHA class IV)&#xD;
&#xD;
          -  Under treatment of systemic steroids&#xD;
&#xD;
          -  Participation in any other clinical trial that might interfere with the results of&#xD;
             this trial&#xD;
&#xD;
          -  Lack of compliance&#xD;
&#xD;
          -  Inability to fill in questionnaires (insufficient command of language, dementia, lack&#xD;
             of time)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Roviello</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Siena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniele Marrelli</last_name>
    <phone>+39577585157</phone>
    <email>daniele.marrelli@unisi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>General and Surgical Oncology Department, University of Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Marrelli</last_name>
      <phone>+39577585157</phone>
      <email>daniele.marrelli@unisi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Siena</investigator_affiliation>
    <investigator_full_name>Franco Roviello</investigator_full_name>
    <investigator_title>Full Professor, Clinical Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

